A French company has announced a new U.S. headquarters in Terre Haute. AMATSIGROUP Inc. Chief Executive Officer Alain Sainsot says the operation, located at an 80-acre former Merck Animal Health facility, will boost the pharmaceutical manufacturer's veterinary studies “by five-fold.” October 1, 2014
TOULOUSE, France – AMATSIGROUP, a dedicated service provider in both human and veterinary drug development sectors, announces the establishment of an operation site in the US in Terre Haute (Indiana) to strengthen its development and expand its portfolio of services for the pharmaceutical industry internationally. The company will start operation on October 1st, 2014 as AMATSIGROUP, Inc.
AMATSIGROUP will duplicate services and expertise in the US site that the AmatsiAvogadro site (near Toulouse, France) offered for over 15 years to Animal Health companies based in Europe and in the US. The new facilities, in Terre Haute, is expected to increase AMATSIGROUP’s capacities and offering as well as its proximity with US clients.
AMATSIGROUP provides its clients a wide range of services covering four complementary strategic activities:
Bioservices: in-life studies (PK, ADME, residue, tolerance) and preclinical and clinical bioanalysis
Pharmaceutical analysis solutions: analytical method development and validation, stability studies, quality control of raw materials and finished products
Formulation development and manufacturing: formulation development and production of sterile and non-sterile pilot batches
Clinical trial material logistics: GMP storage, packaging, labelling, QP release services and international distribution
Alain Sainsot, the CEO of AMATSIGROUP, stated:
“Following the opening of our North American office in 2006, we reinforce the international development of AMATSIGROUP with the integration of an operation site in Terre Haute, IN; this site is already operational and located in the Midwest corridor, a historical area and magnet for the veterinary pharmaceutical industry. With this addition, our capacities for veterinary studies is increased by 5-fold. This will also be the opportunity for AMATSIGROUP to expand its portfolio to veterinary vaccines. By strengthening this settlement, both in Europe and in the US, we increase our proximity with the leading pharmaceutical laboratories by providing them support for their global launches.”
AMATSIGROUP, as a CDMO (Contract Development and Manufacturing Organisation), provides services throughout both preclinical and clinical phases in veterinary and human drugs. AMATSIGROUP, founded in 2010, was formed by the integration of four companies (Avogadro, Amatsi, DBI and Avepharm) bringing complementary expertise. With the reinforcement of more than 200 highly-qualified staff and a diversified portfolio of 600 clients, AMATSIGROUP is the leading French company in its sector.
AMATSIGROUP generates annual sales of 23 million euros (30 million US dollars) and contributes to the development and registration of more than 30 pharmaceutical products for its clients every year. The Group operates from facilities based in the South of France and now in the USA.
For further information, please visit our website www.amatsigroup.com.
Source: AMATSIGROUP Inc.